Table 1.
Baseline clinical characteristics
| Double placebo (n = 18) | Risedronate/testosterone (n = 20) | Risedronate (n = 20) | Testosterone (n = 19) | |
|---|---|---|---|---|
| Age (yr) | 26.9 ± 7.2 | 25.2 ± 6.2 | 25.3 ± 6.3 | 27.1 ± 7.3 |
| Duration of anorexia nervosa (yr) | 5.2 ± 4.3 | 6.3 ± 6.8 | 5.1 ± 5.8 | 6.6 ± 5.5 |
| Oral contraceptive use (%) | 28 | 25 | 25 | 26 |
| Endogenous menses (%) | 13 | 26 | 29 | 21 |
| Bulimic subtype (%) | 39 | 40 | 50 | 26 |
| Activity (MET-h/wk) | 19 ± 12 | 15 ± 11 | 22 ± 16 | 19 ± 12 |
| Weight (kg) | 47.6 ± 5.2 | 47.9 ± 5.4 | 47.2 ± 5.6 | 47.8 ± 5.5 |
| % IBW | 78.9 ± 5.7 | 78.7 ± 7.1 | 78.8 ± 5.7 | 78.7 ± 7.5 |
| BMI (kg/m2) | 17.9 ± 1.2 | 17.8 ± 1.4 | 17.6 ± 1.2 | 17.5 ± 1.8 |
| Lean body mass (kg) | 37.0 ± 4.0 | 37.4 ± 4.3 | 36.7 ± 4.7 | 37.7 ± 4.3 |
| % Body fat | 19.2 ± 4.7 | 18.9 ± 4.1 | 19.2 ± 4.8 | 17.9 ± 5.1 |
| PA spine Z-score | −1.7 ± 0.8 | −1.5 ± 0.9 | −1.6 ± 0.8 | −1.5 ± 1.2 |
| Lateral spine Z-score | −1.7 ± 1.0 | −1.7 ± 1.1 | −1.4 ± 0.6 | −1.2 ± 0.9 |
| Hip Z-score | −1.4 ± 0.6 | −1.4 ± 0.7 | −1.2 ± 1.1 | −1.1 ± 1.0 |
| Radius Z-score | −0.6 ± 1.1 | −0.4 ± 0.8 | −0.6 ± 1.0 | −0.5 ± 0.9 |
| CTX (ng/ml) | 0.61 ± 0.37 | 0.66 ± 0.36 | 0.63 ± 0.40 | 0.53 ± 0.33 |
| P1NP (ng/ml) | 46.8 ± 21.8 | 53.1 ± 23.9 | 57.9 ± 42 | 39.9 ± 17.8 |
IBW, Ideal body weight; MET, metabolic equivalent.